Confidential Investment Opportunity
INVESTMENT OPPORTUNITY
PHARMACEUTICAL MANUFACTURING
PROPRIETARY INVESTMENT MEMORANDUM | NALAGARH, INDIA
M&A ADVISORY SERVICES PROVIDED BY:
CA Dhiraj Ostwal & Co.
YOUR VISION, OUR EXPERTISE— SEAMLESS M&A SOLUTIONS.
PRIVATE & CONFIDENTIAL
NOT AN OFFER FOR SALE
Business Overview
A leading WHO-GMP and ISO-certified pharmaceutical manufacturer with over two decades of operational excellence, serving domestic and international markets with a diverse therapeutic portfolio.
Core Manufacturing Capabilities
Manufacturing Excellence
- State-of-the-art automated production lines
- Tablets, Capsules, Injectables, Ointments, Powders
- Advanced QC and microbiology labs with HPLC, UV, IR spectrophotometers
- Stability chambers and sterility testing setups
- Proven history of successful audits and inspections
- Scalable operations with expansion capacity
Deal Size & Transaction Structure
Complete Sale Opportunity
Reason for Sale
The current promoter is seeking retirement after successfully building the company over two decades. This presents a unique opportunity for strategic investors or pharmaceutical groups to acquire a fully operational, certified manufacturing unit with established domestic and international market presence.
Valuation Rationale
Financial Performance Analysis
Three-Year Financial Performance
| Financial Metric | FY 2021-22 | FY 2022-23 | FY 2023-24 |
|---|---|---|---|
| Revenue (₹ Cr) | 20.0 | 25.0 | 30.0 |
| EBITDA (₹ Cr) | 5.2* | 6.5 | 8.7 |
| PAT (₹ Cr) | 1.05* | 1.31* | 1.75* |
| EBITDA Margin | 26%* | 26% | 29% |
*Calculated based on available financial data and consistent margin application
Revenue Contribution by Product Category
Strong Growth Trajectory: Consistent revenue growth with improving profitability margins. EBITDA margin expanded from 26% to 29% in FY2024.
Product Portfolio
Therapeutic Segments
| Therapeutic Category | Key Products | Market Focus |
|---|---|---|
| Anti-infectives / Antibiotics | Ceflosporin Injectables, Tablets | Domestic & Export |
| Cardiovascular | Hypertension, Cholesterol medications | Domestic & Export |
| Anti-diabetics | Oral hypoglycemic agents | Domestic & Export |
| Dermatology | Ointments, Lotions, Creams | Domestic & Export |
| Gastrointestinal | Antacids, Anti-ulcer medications | Domestic |
| Gynecology | Hormonal treatments | Domestic |
| Pediatrics | Syrups, Pediatric formulations | Domestic |
| Orthopedics | Pain management, Anti-inflammatory | Domestic |
| Anti-malarial | Malaria prophylaxis & treatment | Export (Africa) |
| General Wellness | Multivitamins, Nutritional supplements | Domestic & Export |
Dosage Forms & Manufacturing Capacity
Customer & Geographical Portfolio
Revenue Distribution
Key Markets Presence
Domestic Operations
PAN-India franchise and distribution network covering all major states. Strong presence in both urban and rural markets with diverse therapeutic offerings.
International Export Markets
- Philippines - Established market since 2012
- Georgia - Key CIS country presence
- Uzbekistan - Growing Central Asian market
- Myanmar - Southeast Asian foothold
- Yemen - Middle East presence
- Afghanistan - Regional market
- African Markets - Multiple countries
- CIS Countries - Regional bloc presence
Market Development Status
Business Potential - SWOT Analysis
Strengths
- WHO-GMP and ISO certifications ensuring global quality compliance
- Proven track record of timely delivery and reliable supply chain
- Diverse product portfolio across multiple therapeutic segments
- Established domestic and international market presence
- Modern manufacturing facility with scalability
- Strong regulatory compliance history with RBI clearance
Weaknesses
- Requires investment for scaling operations to next level
- Limited brand recognition compared to multinational pharma companies
- Dependence on external API suppliers for certain formulations
- Need for continuous regulatory investment to maintain certifications
Opportunities
- Many smaller units closing due to non-compliance, creating market share acquisition opportunities
- Growing demand for affordable generic medicines in emerging markets
- Expansion potential in African markets with high growth prospects
- Contract manufacturing growth from ₹100 Cr to ₹1,000 Cr by 2030
- API manufacturing vertical integration opportunity
- New product launches with estimated ₹50 Cr annual sales potential
Threats
- Regular compliance requirements and changing regulatory landscapes
- Increasing competition from larger pharmaceutical conglomerates
- Price controls and regulatory pressures in domestic market
- Supply chain disruptions affecting raw material availability
- Currency fluctuations impacting export profitability
Growth Strategy & Future Roadmap
Expansion Plans
Planned Capital Investments
- Pallet Manufacturing Plant: Dedicated unit for solid oral dosage portfolio expansion
- Liquid Injectable Plant: New facility to expand capacity in high-growth segment
- API Bulk Drug Facility: Vertical integration for supply security and margin improvement
- Automation Enhancement: Further automation of production lines for efficiency
- R&D Expansion: Strengthening formulation development capabilities
Strategic Growth Milestones
| Year | Milestone |
|---|---|
| 1999 | Origin as franchise marketing initiative |
| 2005 | Incorporated as Pharmaceutical Manufacturing Company |
| 2012 | Expanded internationally - Philippines, Myanmar |
| 2015 | Expanded portfolio to 1,400+ registered products |
| 2023 | Achieved ₹25 Cr revenue milestone |
| 2024 | Crossed ₹30 Cr revenue with 29% EBITDA margin |
Investment Highlights
Why Invest?
Two decades of pharmaceutical manufacturing excellence with WHO-GMP certification, diverse product portfolio, and established domestic & international market presence
Key Investment Merits
Growth Catalysts
- Market Consolidation: Acquisition opportunity due to smaller units closing from non-compliance
- Export Market Expansion: Focus on high-growth African markets with existing registrations
- Contract Manufacturing Growth: Target to grow from ₹100 Cr to ₹1,000 Cr by 2030
- Vertical Integration: API manufacturing plant for supply security and margin improvement
- New Product Launches: Pipeline products with ₹50 Cr annual sales potential
OUR PROFILE
CA Dhiraj Ostwal & Co. specializes in providing comprehensive M&A advisory services, helping businesses unlock value through strategic acquisitions, divestitures, and growth partnerships. With deep industry expertise and a commitment to seamless execution, we bridge the gap between vision and reality.
CA DHIRAJ OSTWAL & Co.
Your Vision, Our Expertise— Seamless M&A Solutions.
**Private & Confidential:** This document contains confidential information and is not an offer for sale.
Pharmaceutical Manufacturing | Private & Confidential
CA Dhiraj Ostwal & Co. (M&A Advisory)